RT Journal Article
T1 The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
A1 Zijlstra, Josée M
A1 Follows, George
A1 Casasnovas, Rene-Olivier
A1 Vermaat, Joost S P
A1 Kalakonda, Nagesh
A1 Choquet, Sylvain
A1 Hill, Brian
A1 Thieblemont, Catherine
A1 Cavallo, Federica
A1 Cruz, Fatima De la
A1 Kuruvilla, John
A1 Hamad, Nada
A1 Jaeger, Ulrich
A1 Caimi, Paolo
A1 Gurion, Ronit
A1 Warzocha, Krzysztof
A1 Bakhshi, Sameer
A1 Sancho, Juan-Manuel
A1 Schuster, Michael
A1 Egyed, Miklos
A1 Offner, Fritz
A1 Vassilakopoulos, Theodoros P
A1 Samal, Priyanka
A1 Ku, Matthew
A1 Xu, Jenny
A1 Corona, Kelly
A1 Chamoun, Kamal
A1 Shah, Jatin
A1 Canales, Miguel
A1 Maerevoet, Marie
K1 SADAL study
K1 diffuse large B-cell lymphoma
K1 exportin 1
K1 selinexor
AB Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients  ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL.
SN 2072-6694
YR 2022
FD 2022-02-04
LK http://hdl.handle.net/10668/20872
UL http://hdl.handle.net/10668/20872
LA en
DS RISalud
RD Mar 14, 2025